Lumoxiti Alternatives Compared
| Lumoxiti (moxetumomab pasudotox) | Cladribine | Intron A (interferon alfa-2b) |
|
|---|
| Lumoxiti (moxetumomab pasudotox) | Cladribine | Intron A (interferon alfa-2b) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hairy Cell Leukemia. Lumoxiti may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis, Hairy Cell Leukemia. Cladribine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, Angioblastoma, Condylomata Acuminata, Hairy Cell Leukemia, Hepatitis B, Hepatitis C, Immune... View more |
Related suggestions Hairy Cell Leukemia
|
|||||||
| More about Lumoxiti (moxetumomab pasudotox) | More about Cladribine | More about Intron A (interferon alfa-2b) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Cladribine has an average rating of 8.6 out of 10 from a total of 9 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 11% reported a negative effect. |
Intron A has an average rating of 3.3 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 75% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Lumoxiti side effects |
View all Cladribine side effects |
View all Intron A side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
Lower cost generic |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Cladribine prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
|
|
||||||||
| Brand Names | ||||||||||
|
N/A |
Cladribine Novaplus, Mavenclad |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
1.4 hours |
6.7 hours |
3 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 72 drugs are known to interact with Lumoxiti:
|
A total of 499 drugs are known to interact with Cladribine:
|
A total of 260 drugs are known to interact with Intron A:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
September 13, 2018 |
March 29, 2019 |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.